Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00310401 · ClinicalTrials.gov registry record · Phase 2
The Effect of Nebulized Albuterol on Donor Oxygenation
A Phase 2 study, sponsored by Vanderbilt University Medical Center.
- Completed
- Registry status
- Phase 2
- Development phase
- 506
- Enrollment target
NCT00310401: Completed Phase 2 study, sponsored by Vanderbilt University Medical Center.
NCT00310401 is a Phase 2 study that has completed, run by Vanderbilt University Medical Center. The registered enrollment target is 506 participants, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (280% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00310401, a Phase 2 study, has completed, sponsored by Vanderbilt University Medical Center.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 506 participants
- Enrollment target
Study Summary
The purpose of this study is to test the effectiveness of albuterol versus placebo with the following specific aims: a) Treatment of brain dead organ donors with albuterol will reduce pulmonary edema, improve donor oxygenation, and increase the number of lungs available for transplantation, b) Developing a blood test to predict the development of primary graft dysfunction in lung transplant recipients, and c) treating brain dead organ donors with albuterol will decrease markers of primary graft dysfunction and lead to improved lung transplant recipient outcomes and to higher rates of lungs suitable for transplantation.
Primary Outcome
The primary outcome was the change in oxygenation as measured by change in the PaO2/FiO2 ratio from study enrollment to organ procurement
Interventions
- DRUG Saline
- DRUG Albuterol
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 506 participants |
| Start Date | 2007-04 |
| Est. Completion | 2011-06 |
| Phase | Phase 2 |
What the finished NCT00310401 record still lists
NCT00310401 is an interventional study that assigns participants to a tested intervention. The registered 506 participants enrollment target is mid-sized for trials with a published cap, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (280% higher).
The record links to 0 conditions, and to 2 interventions - of which Saline is the first listed.
NCT00310401 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00310401 about?
NCT00310401 is a clinical study titled "The Effect of Nebulized Albuterol on Donor Oxygenation". The purpose of this study is to test the effectiveness of albuterol versus placebo with the following specific aims: a) Treatment of brain dead organ donors with albuterol will reduce pulmonary edema, improve donor oxygenation, and increase the number of lungs available for transplantation, b) Devel...
What is the current status of trial NCT00310401?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 506 participants. The study started on 2007-04. Estimated completion is 2011-06.
What interventions are being tested in trial NCT00310401?
The interventions under investigation include: Saline (DRUG), Albuterol (DRUG).
Who is sponsoring clinical trial NCT00310401?
This trial is sponsored by Vanderbilt University Medical Center, which has 677 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00310401's enrollment target sits among peer trials
506 69th of 2000 higher than 1,932 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT05069428 · 506 participants · Phase 4
Delirium Reduction With Ramelteon
- NCT05797168 · 506 participants · Phase 1
Phase I/IIa Study of AZD5335 as Monotherapy and Combination Therapy in Participants With Solid Tumors
- NCT06164717 · 507 participants · NA
Behavioral and Neural Characteristics of Adaptive Speech Motor Control
- NCT02115295 · 508 participants · Phase 2
Cladribine, Idarubicin, Cytarabine, and Venetoclax in Treating Patients With Acute Myeloid Leukemia, High-Risk Myelodysplastic Syndrome, or Blastic Phase Chronic Myeloid Leukemia
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia